Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small-cell lung cancer
この論文をさがす
抄録
application/pdf
Non-small cell lung cancer (NSCLC) is one of the leading causes of death in all lung cancer patients due to its metastatic spread. Even though cisplatin treatment after surgical resection of the primary tumor has been established as a standard chemotherapy for residual disease including metastatic spread, NSCLC often acquires a resistance against chemotherapy, and metastatic disease is often observed. Amongst many potential mechanisms, epithelial-to-mesenchymal transition (EMT) has been considered as an important process in acquiring both metastatic spread and chemo-resistance of NSCLC. In this study, we identified MCL-1 as a critical molecule for chemoresistance in A549 cells associated with TGF-β-induced EMT. Importantly, downregulation of MCL-1 by siRNA or inhibition of MCL-1 with pan-BCL2 inhibitor to inhibit MCL-1 was able to overcome the EMT-associated chemo-resistance in A549 cells. Collectively, MCL-1 can be a new therapeutic target for overcoming EMT-associated chemo-resistance in NSCLC patients in the context of post-operative chemotherapies.
Article
International Journal of Oncology, 2015 Apr; 46(4): 1844-8
収録刊行物
-
- International Journal of Oncology
-
International Journal of Oncology 46 (4), 1844-1848, 2015-04
Spandidos Publications
- Tweet
詳細情報
-
- CRID
- 1050564289059345024
-
- NII論文ID
- 120006389606
-
- NII書誌ID
- AA10992511
-
- ISSN
- 10196439
-
- HANDLE
- 10110/00018126
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- IRDB
- CiNii Articles